Lixte Biotechnology Warrants
LIXTW
LIXTW was delisted on the 26th of November, 2025.
3 hedge funds and large institutions have $9.42K invested in Lixte Biotechnology Warrants in 2023 Q2 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 1 reducing their positions, and 2 closing their positions.
29% more capital invested
Capital invested by funds: $7.32K → $9.42K (+$2.1K)
0.18% more ownership
Funds ownership: 0.53% → 0.71% (+0.18%)
25% less funds holding
Funds holding: 4 → 3 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EFG
Ethos Financial Group
King Of Prussia,
Pennsylvania
|
+$3.07K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$664 |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$70 |
| 3 |
CS
Clear Street
New York
|
-$7 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
WAM
1
Warberg Asset Management
Winnetka,
Illinois
| $3.71K | – | – | – |
|
|
EFG
2
Ethos Financial Group
King Of Prussia,
Pennsylvania
| $3.63K | +$3.07K | +42,105 | New |
|
|
CS
3
Clear Street
New York
| $2.08K | -$7 | -100 | -0.4% |
|
|
4
Citadel Advisors
Miami,
Florida
| – | -$664 | -11,067 | Closed |
|
|
5
UBS Group
Zurich,
Switzerland
| – | -$70 | -811 | Closed |
|
LIXTW Hedge Fund Activity: Q2 2023 in Review
3 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Lixte Biotechnology Warrants (LIXTW) for Q2 2023, worth a combined $9.42K — up 29% from $7.32K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of LIXTW and 1 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 0 added.
The largest buyer was Ethos Financial Group, opening a new position worth an estimated $3.07K. The largest seller was Citadel Advisors, exiting entirely with an estimated $664 sold.
- 3 institutional investors held Lixte Biotechnology Warrants (LIXTW) as of Q2 2023, down from 4 in Q1 2023.
- Funds reported $9.42K of Lixte Biotechnology Warrants stock for Q2 2023, up 29% quarter-over-quarter.
- 1 fund opened new Lixte Biotechnology Warrants positions in Q2 2023 and 2 closed out, a net change of -1 holder.
- The largest Lixte Biotechnology Warrants buyer in Q2 2023 was Ethos Financial Group, an estimated $3.07K added.
- The largest Lixte Biotechnology Warrants seller in Q2 2023 was Citadel Advisors, an estimated $664 sold.
Based on aggregated 13F filings for Q2 2023.